Plain-English translation of NCT07260877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, can help reduce skin rashes and symptoms in people who have cutaneous lupus erythematosus. Researchers want to see if the medication works better than a placebo (a dummy pill that looks identical but contains no active drug) and to understand what side effects people experience. About 24 adults will participate in this study.
Cutaneous lupus is a chronic skin condition that can be hard to treat and significantly affect quality of life. This trial is exploring whether this new treatment might offer relief for people whose skin symptoms are currently active and not adequately controlled.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic once a month for 12 weeks. For the first 4 weeks, you'll randomly receive either the new medication or a placebo (you won't know which). After 4 weeks, everyone switches to taking the new medication for the remaining 8 weeks. During each visit, your doctor will check on your skin symptoms, perform tests, and monitor you for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States